RISCA, GIULIA
 Distribuzione geografica
Continente #
EU - Europa 362
AS - Asia 201
NA - Nord America 119
SA - Sud America 7
OC - Oceania 2
Totale 691
Nazione #
IT - Italia 176
SG - Singapore 121
US - Stati Uniti d'America 118
GB - Regno Unito 56
IE - Irlanda 33
RU - Federazione Russa 33
HK - Hong Kong 28
DE - Germania 26
CN - Cina 20
ID - Indonesia 16
NL - Olanda 12
JP - Giappone 10
FI - Finlandia 8
BR - Brasile 6
AT - Austria 4
BE - Belgio 4
PH - Filippine 3
AU - Australia 2
CZ - Repubblica Ceca 2
FR - Francia 2
IN - India 2
PL - Polonia 2
RO - Romania 2
CA - Canada 1
EC - Ecuador 1
ES - Italia 1
JO - Giordania 1
LT - Lituania 1
Totale 691
Città #
Singapore 111
Milan 49
Dublin 33
Coventry 30
Hong Kong 26
Santa Clara 26
Jakarta 16
Shanghai 12
Florence 11
Frankfurt am Main 11
Lambeth 8
Melzo 8
New York 8
Helsinki 7
Messina 7
Munich 7
Rome 6
Piacenza 5
Bath 4
Berlin 4
Brussels 4
Caronno Pertusella 4
Kyoto 4
Romola 4
West Jordan 4
Ashburn 3
Bedford 3
Chicago 3
Cinisello Balsamo 3
Lainate 3
Manila 3
Naples 3
San Jose 3
Scandicci 3
Sesto San Giovanni 3
Vienna 3
Acquafredda 2
Aversa 2
Biandronno 2
Bloemendaal 2
Brno 2
Cambridge 2
Castelfranco Emilia 2
Cesano Maderno 2
Cluj-Napoca 2
Fort Worth 2
Grassobbio 2
Hirosaki 2
Los Angeles 2
Nagasaki 2
Paris 2
Pavia 2
Seregno 2
Shenzhen 2
Slough 2
Sulmona 2
Sydney 2
Tokyo 2
Vercelli 2
Warsaw 2
Alvorada 1
Amman 1
Amsterdam 1
Belo Horizonte 1
Bonndorf 1
Brugherio 1
Byron Center 1
Casalecchio di Reno 1
Catania 1
Cernusco sul Naviglio 1
Chennai 1
Cormano 1
Curitiba 1
Cusano Milanino 1
Dallas 1
Falkenstein 1
Genoa 1
Groningen 1
Indore 1
Islington 1
Lappeenranta 1
Lissone 1
London 1
Madrid 1
Mariano Comense 1
Memphis 1
Monza 1
North Bergen 1
Ottawa 1
Oxford 1
Pioltello 1
Prineville 1
Quito 1
Rio Paranaíba 1
Shijiazhuang 1
Springfield 1
São José dos Campos 1
São Paulo 1
Terni 1
Tremestieri Etneo 1
Totale 530
Nome #
Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B 82
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 77
Towards the Definition of the Molecular Hallmarks of Idiopathic Membranous Nephropathy in Serum Proteome: A DIA-PASEF Approach 70
BIVARIATE COPULA MODELS IN THE PRESENCE OF COMPLEX PATTERNS FOR THE SURROGATE ENDPOINT FOR A SURVIVAL TRUE ENDPOINT 69
DIA-PASEF mass spectrometry as a tailored proteomic approach to explore Idiopathic Membranous Nephropathy 69
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 68
Basket trials in very rare diseases: are they feasible? 63
Deep immunophenotypic characterization of CARCIK-CD19 pre-infusion cellular product by advanced multiparametric flow cytometry 50
Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome 49
Validation of a skewed surrogate endpoint for a time-to-event outcome: the use of a Zaga distribution 42
Plasma proteomic signatures related to COVID-19 disease severity by an untargeted nLC-ESI-MS/MS approach 35
Multicentric Longitudinal Prospective Study in a European Cohort of MYO7A Patients: Disease Course and Implications for Gene Therapy 33
Reference Values of Ceruloplasmin across the Adult Age Range in a Large Italian Healthy Population 18
Data analysis optimisation of a DIA-PASEF mass spectrometry approach for the study of idiopathic membranous nephropathy disease 10
Totale 735
Categoria #
all - tutte 3.930
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.930


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202324 0 0 0 0 0 0 0 0 1 6 11 6
2023/2024250 7 11 5 15 19 49 36 17 17 26 23 25
2024/2025461 36 89 78 76 71 70 41 0 0 0 0 0
Totale 735